Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

被引：0
|
作者：
Mathilde Bureau
Thierry Chatellier
Tanguy Perennec
Thomas Goronflot
Charlotte Greilsamer
Anne-Laure Chene
Raafet Affi
Eric Frampas
Jaafar Bennouna
Elvire Pons-Tostivint
机构：
[1] University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de Nantes
[2] Medical Oncology Unit,Department of Radiation Oncology
[3] Institut de Cancerologie de L’Ouest,INSERM
[4] University Hospital of Nantes,Pneumology Unit
[5] Medical Oncology Unit,Radiology Unit
[6] University Hospital of Nantes,undefined
[7] University Hospital of Nantes,undefined
[8] INSERM,undefined
[9] CRCINA,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Baseline tumour size; Non-small cell lung cancer; Immune checkpoint inhibitor; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1747 / 1756
页数：9
相关论文
共 50 条
  • [31] Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (≥ 50%) non-small cell lung cancer.
    De Castro Barrichello, Adriana Paula
    Alessi, Joao Victor Machado
    Ricciuti, Biagio
    Pecci, Federica
    Vaz, Victor R.
    Lamberti, Giuseppe
    Turner, Madison M.
    Pfaff, Kathleen L.
    Rodig, Scott J.
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec's University Teaching Hospitals (DALP-First Study)
    Berard, Ghislain
    Guevremont, Chantal
    Marcotte, Nathalie
    Schroeder, Coleen
    Bouchard, Nicole
    Rajan, Raghu
    CURRENT ONCOLOGY, 2023, 30 (03) : 3251 - 3262
  • [33] Hospitalization for immune related toxicity and overall survival (OS) among patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab
    Khorasanchi, Adam
    Zhao, Songzhu
    Wei, Lai
    Li, Mingjia
    Ho, Kevin
    Abu-Sbeih, Hamzah
    Alexander, John Howard
    Goodyear, Evelyn
    Secor, Austin
    Shields, Peter G.
    He, Kai
    Kaufman, Jacob
    Memmott, Regan Michelle
    Alahmadi, Asrar
    Carbone, David Paul
    Otterson, Gregory Alan
    Meara, Alexa Simon
    Presley, Carolyn J.
    Owen, Dwight Hall
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression
    Ikezawa, Yasuyuki
    Mizugaki, Hidenori
    Morita, Ryo
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Kitamura, Yasuo
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Furuta, Megumi
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Shimokawa, Mototsugu
    Oizumi, Satoshi
    CANCER SCIENCE, 2022, 113 (06) : 2109 - 2117
  • [35] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [36] PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy
    Vrankar, M.
    Zwitter, M.
    Kern, I
    Stanic, K.
    NEOPLASMA, 2018, 65 (01) : 140 - 146
  • [37] Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50%
    Zarogoulidis, Paul
    Papadopoulos, Vasilis
    Maragouli, Elena
    Papatsibas, George
    Sardeli, Chrysanthi
    Man, Yan-Gao
    Bai, Chong
    Huang, Haidong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S28 - S30
  • [38] Prognostic implication of PD-L1 polymorphisms in non-small cell lung cancer treated with radiotherapy
    Kang, Min Kyu
    Lee, Shin Yup
    Choi, Jin Eun
    Do, Sook Kyung
    Cho, Moon-June
    Kim, Jun-Sang
    Park, Jae Yong
    CANCER MEDICINE, 2021, 10 (22): : 8071 - 8078
  • [39] Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced nonsmall cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone
    Bureau, M.
    Chatelier, T.
    Perennec, T.
    Goronflot, T.
    Greilsamer, C.
    Chene, A-L.
    Affi, R.
    Bennouna, J.
    Pons-Tostivint, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1004 - S1004
  • [40] Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy
    Li, Mingjia
    Zhao, Songzhu
    Lopez, Gabrielle
    Secor, Austin
    Das, Parthib
    Surya, Nitya
    Grogan, Madison
    Patel, Sandip
    Chakravarthy, Karthik
    Miah, Abdul
    Spakowicz, Daniel
    Tinoco, Gabriel
    Li, Zihai
    Wei, Lai
    He, Kai
    Bertino, Erin
    Alahmadi, Asrar
    Memmott, Regan
    Kaufman, Jacob
    Shields, Peter G.
    Carbone, David P.
    Presley, Carolyn J.
    Otterson, Gregory A.
    Owen, Dwight H.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2067 - 2074
12345